(4S,4'S)-1,1',4,4'-Tetraisopropyl-4,4',5,5'-tetrahydro-1H,1'H-2,2'-biimidazole, 97%, 250mg

AZTREONAM, 95%, 25g

DICYCLOPROPYLMETHANAMINE, 95.0%, 10g

1-Benzylpiperidine-3-carboxylic acid, 95.0%, 5g

Siringa da microlitro GASTIGHT® serie 1700 Point tipo 2, 25 µl, 1702 RN, 1 pezzo

1-Butyl-1-methylpiperidinium Bis(trifluoromethanesulfonyl)imide>98.0%(T)5g

5-(1-hydroxyethyl)imidazolidine-2,4-dione, 95.0%, 1g

trans-4-Isopropylcyclohexanecarboxylic Acid>98.0%(GC)(T)25g

Sodium 3-Hydroxy-2-naphthoate>98.0%(HPLC)(T)5g

3-(4-chlorophenyl)-4-[(furan-2-yl)methyl]-4,5-dihydro-1H-1,2,4-triazole-5-thione, 97%, 100mg

(2E)-1-(2,4-dimethoxyphenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one, 95.0%, 10g

Glycine, N-[[3-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methyl]-N-(methoxycarbonyl)-, 25mg

4-Phenyl-1,2,4-triazolidine-3,5-dione, 95.0%, 5g